secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2022-10-19T23:59:59+00:00
Accession:  0001193125-22-264875
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz licenses zanidatamab from Zymeworks for up to $1.76B; $50M upfront, $325M option payment
--------------------------------------------------------------------------------

- Exclusive rights in U.S., Europe, Japan for HER2-targeted bispecific antibody zanidatamab.
- Zymeworks eligible for $50M upfront, $325M option payment after HERIZON-BTC-01 data, plus up to $1.39B milestones.
- Tiered royalties of 10%-20% on net sales; deal expected to close in 2022 subject to HSR clearance.
- Zanidatamab in pivotal trials for biliary tract cancer and gastroesophageal adenocarcinoma.
- FDA Breakthrough Therapy and Fast Track designations; top-line BTC data expected by end of 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312522264875/0001193125-22-264875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312522264875/d496602d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-264875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer